Combination of fulvestrant and lapatinib in non-HER2-overexpressing and adriamycin-resistant breast cancer cell lines

MLA

Anna Emde, et al. “Combination of Fulvestrant and Lapatinib in Non-HER2-Overexpressing and Adriamycin-Resistant Breast Cancer Cell Lines.” Journal of Clinical Oncology, vol. 25, June 2007, p. 14050. EBSCOhost, https://doi.org/10.1200/jco.2007.25.18_suppl.14050.

APA

Anna Emde, K. Maslak, A. E. Reles, Kurt Possinger, Jan Eucker, & Hongyu Liu. (2007). Combination of fulvestrant and lapatinib in non-HER2-overexpressing and adriamycin-resistant breast cancer cell lines. Journal of Clinical Oncology, 25, 14050. https://doi.org/10.1200/jco.2007.25.18_suppl.14050

Chicago

Anna Emde, K. Maslak, A. E. Reles, Kurt Possinger, Jan Eucker, and Hongyu Liu. 2007. “Combination of Fulvestrant and Lapatinib in Non-HER2-Overexpressing and Adriamycin-Resistant Breast Cancer Cell Lines.” Journal of Clinical Oncology 25 (June): 14050. doi:10.1200/jco.2007.25.18_suppl.14050.